Patents by Inventor Meena Subramanyam

Meena Subramanyam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nausea and Vomiting Management System
    Publication number: 20230395254
    Abstract: A method (500) for managing nausea includes receiving, from one or more monitoring devices (200), patient parameter data (212) of a patient (10). The patient parameter data is collected by the one or more monitoring devices. The method also includes determining, based on the patient parameter data of the patient, whether the patient is experiencing or about to experience an episode of nausea. When the patient is experiencing or about to experience an episode of nausea, the method also includes communicating one or more therapy signals (302, 304, 306, 308) to a receiver device (12, 21, 400) in communication with the computing device.
    Type: Application
    Filed: July 27, 2021
    Publication date: December 7, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Jordan Brayanov, Cristina Menchero Almansa, Meena Subramanyam
  • Methods and products for evaluating an immune response to a therapeutic protein
    Patent number: 11686734
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: June 27, 2023
    Assignee: BIOGEN MA INC.
    Inventors: Meena Subramanyam, Lakshimi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
  • ASSAY FOR JC VIRUS ANTIBODIES
    Publication number: 20220397571
    Abstract: The invention relates to methods and reagents for analyzing samples for the presence of JC virus antibodies.
    Type: Application
    Filed: March 25, 2022
    Publication date: December 15, 2022
    Inventors: Leonid GORELIK, Kenneth J. SIMON, Meena SUBRAMANYAM, Mia Marie RUSHE
  • METHOD OF ASSESSING RISK OF PML
    Publication number: 20220357339
    Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
    Type: Application
    Filed: March 21, 2022
    Publication date: November 10, 2022
    Inventors: Gary Lewis BLOOMGREN, Carmen BOZIC, Sophia LEE, Amy PACE, Tatiana PLAVINA, Meena SUBRAMANYAM
  • Assay for JC virus antibodies
    Patent number: 11287423
    Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: March 29, 2022
    Assignee: Biogen MA Inc.
    Inventors: Leonid Gorelik, Kenneth J. Simon, Meena Subramanyam, Mia Marie Rushe
  • Method of assessing risk of PML
    Patent number: 11280794
    Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: March 22, 2022
    Assignee: Biogen MA Inc.
    Inventors: Gary Lewis Bloomgren, Carmen Bozic, Sophia Lee, Amy Pace, Tatiana Plavina, Meena Subramanyam
  • METHOD OF ASSESSING RISK OF PML
    Publication number: 20220011310
    Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
    Type: Application
    Filed: August 3, 2021
    Publication date: January 13, 2022
    Inventors: Gary Lewis Bloomgren, Carmen Bozic, Sophia Lee, Meena Subramanyam, Tatiana Plavina
  • ASSAY FOR JC VIRUS ANTIBODIES
    Publication number: 20210102939
    Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.
    Type: Application
    Filed: October 7, 2019
    Publication date: April 8, 2021
    Inventors: Leonid GORELIK, Kenneth J. SIMON, Meena SUBRAMANYAM, Mia Marie RUSHE
  • METHODS AND PRODUCTS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC PROTEIN
    Publication number: 20210025900
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
    Type: Application
    Filed: July 7, 2020
    Publication date: January 28, 2021
    Inventors: Meena Subramanyam, Lakshimi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
  • METHOD OF ASSESSING RISK OF PML
    Publication number: 20200408776
    Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
    Type: Application
    Filed: June 8, 2020
    Publication date: December 31, 2020
    Inventors: Gary Lewis BLOOMGREN, Carmen BOZIC, Sophia LEE, Amy PACE, Tatiana PLAVINA, Meena SUBRAMANYAM
  • Methods and products for evaluating an immune response to a therapeutic protein
    Patent number: 10705095
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: July 7, 2020
    Assignee: BIOGEN MA INC.
    Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
  • Method of assessing risk of PML
    Patent number: 10677803
    Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: June 9, 2020
    Assignee: Biogen MA Inc.
    Inventors: Gary Lewis Bloomgren, Carmen Bozic, Sophia Lee, Amy Pace, Tatiana Plavina, Meena Subramanyam
  • Assay for JC virus antibodies
    Patent number: 10444234
    Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: October 15, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Leonid Gorelik, Kenneth J. Simon, Meena Subramanyam, Mia Marie Rushe
  • METHOD OF ASSESSING RISK OF PML
    Publication number: 20190227064
    Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
    Type: Application
    Filed: December 5, 2018
    Publication date: July 25, 2019
    Inventors: Gary Lewis Bloomgren, Carmen Bozic, Sophia Lee, Meena Subramanyam, Tatiana Plavina
  • METHOD OF ASSESSING RISK OF PML
    Publication number: 20190137511
    Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
    Type: Application
    Filed: August 28, 2018
    Publication date: May 9, 2019
    Inventors: Gary Lewis BLOOMGREN, Carmen BOZIC, Sophia LEE, Amy PACE, Tatiana PLAVINA, Meena SUBRAMANYAM
  • Method of assessing risk of PML
    Patent number: 10119976
    Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: November 6, 2018
    Assignee: Biogen MA Inc.
    Inventors: Gary Lewis Bloomgren, Carmen Bozic, Sophia Lee, Amy Pace, Tatiana Plavina, Meena Subramanyam
  • METHODS AND PRODUCTS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC PROTEIN
    Publication number: 20180088127
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
    Type: Application
    Filed: June 7, 2017
    Publication date: March 29, 2018
    Applicant: Biogen MA Inc.
    Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
  • Methods and products for evaluating an immune response to a therapeutic protein
    Patent number: 9709575
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titer of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titer of untreated patients increased by the double of the standard deviation of this control antibody titer.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: July 18, 2017
    Assignee: Biogen MA Inc.
    Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
  • ASSAY FOR JC VIRUS ANTIBODIES
    Publication number: 20160187337
    Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.
    Type: Application
    Filed: March 8, 2016
    Publication date: June 30, 2016
    Inventors: Leonid Gorelik, Kenneth J. Simon, Meena Subramanyam, Mia Marie Rushe
  • METHOD OF ASSESSING RISK OF PML
    Publication number: 20160116483
    Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
    Type: Application
    Filed: May 27, 2014
    Publication date: April 28, 2016
    Inventors: Gary Lewis Bloomgren, Carmen Bozic, Sophia Lee, Amy Pace, Tatiana Plavina, Meena Subramanyam